Please login to the form below
David Noble to leave Edelman
David Noble, managing director of Edelman's BioScience division has been made redundant as part of a management restructure
David Noble, managing director of Edelman's BioScience division has been made redundant as part of a management restructure.
Noble has been heading the agency's specialist medical communications business unit for more than three years. He is to leave this month following a three-week consultation process.
Steve Spurr who leads Edleman's ethical healthcare division will take over Noble's responsibilities.
Robert Phillips, Edelman UK CEO told PR Week: "The BioScience and Rx divisions will remain separate, but will be headed by Steve. We are reorganising internally to have more fluent interaction between the teams."
The BioScience division specialises in advisory board management, clinical trial recruitment/retention, market access support, publication planning, meetings and symposia.
Share
Related Hub content
COVID-19 Updates and Daily News
Featured jobs
-
Healthcare Lead Copywriter
-
Competitive
-
Healthcare Senior Account Manager
-
Competitive
-
Medical Editor
-
Competitive
-
Healthcare Account Director
-
Competitive
- EU secures 405 million doses of CureVac’s COVID-19 vaccine
- Novartis and smartpatient launch app experience for wet AMD patients
- Pfizer helps fund biotech venture from former researchers at closed Kent facility
- GSK chief exec ‘optimistic’ COVID-19 vaccine could be available next year
- Chief investigator of Oxford Vaccine Group says data could be released before Christmas
- FDA delays BMS’ liso-cel decision, citing COVID-19 travel restrictions
- New from the PhRMA: Diversity in clinical trials principles summarised
- Lilly’s repurposed COVID-19 med baricitinib bags FDA emergency approval
- Building a brighter future for rare disease patients
- Pfizer, BioNTech to submit emergency use request for COVID-19 vaccine to FDA today
- Pierre Fabre’s Braftovi scores NICE backing for BRAF+ colorectal cancer
- FDA delays BMS’ liso-cel decision, citing COVID-19 travel restrictions
PMHub
Cuttsy + Cuttsy
How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...
Latest intelligence
- New from the PhRMA: Diversity in clinical trials principles summarised
- In November 2020, PhRMA announced the first-ever, industry-wide principles on clinical trial diversity. The principles were approved by the PhRMA Boards of Directors and will take effect in April 2021....
- New from the FDA: Diversity in clinical trials guidance summarised
- In November 2020, the FDA released guidance to enable greater diversity in clinical trials through changes to eligibility criteria, enrolment practices, and trial designs....
- 5 steps to effective clinical trial branding
- When recruiting patients for your clinical trial, you want the materials and information around it to be seen as reputable and professional. To make it clear what the clinical trial...
Quick links
Infographics
